Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

Achyut Guleri, Riccardo Utili, Pascal Dohmen, Nicola Petrosillo, Cornelia Piper, Rashidkhan Pathan, Kamal Hamed

Research output: Contribution to journalArticle

Abstract

Introduction: The European Cubicin® Outcomes Registry and Experience (EU-CORESM) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE). Methods: Data from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Adverse events (AEs) were recorded during treatment and for up to 30 days post-treatment; follow-up data were collected for 2 years. Results: Of 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with both right- and left-sided IE (BRLIE). Overall clinical success was achieved in 80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%). Success rates for methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7% and 66.6% in patients with RIE, LIE and BRLIE, respectively. The overall sustained clinical success rate in patients followed for up to 2 years was 86.7% (RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs deemed possibly related to daptomycin in the investigator’s opinion were reported in 2 (1.3%) RIE, 18 (4.3%) LIE and 1 (2.1%) BRLIE patients. There were 11 (1.8%) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly related to daptomycin. Conclusion: Data from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.

Original languageEnglish
Pages (from-to)283-296
Number of pages14
JournalInfectious Diseases and Therapy
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 26 2015

Fingerprint

Daptomycin
Endocarditis
Registries
Patient Rights
Therapeutics
Methicillin-Resistant Staphylococcus aureus
Infection
Latin America
Gram-Positive Bacteria
Creatine Kinase
Multicenter Studies
Research Personnel
Safety

Keywords

  • Daptomycin
  • Endocarditis
  • EU-CORE
  • Left-sided endocarditis
  • Right-sided endocarditis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Daptomycin for the Treatment of Infective Endocarditis : Results from European Cubicin® Outcomes Registry and Experience (EU-CORE). / Guleri, Achyut; Utili, Riccardo; Dohmen, Pascal; Petrosillo, Nicola; Piper, Cornelia; Pathan, Rashidkhan; Hamed, Kamal.

In: Infectious Diseases and Therapy, Vol. 4, No. 3, 26.09.2015, p. 283-296.

Research output: Contribution to journalArticle

Guleri, Achyut ; Utili, Riccardo ; Dohmen, Pascal ; Petrosillo, Nicola ; Piper, Cornelia ; Pathan, Rashidkhan ; Hamed, Kamal. / Daptomycin for the Treatment of Infective Endocarditis : Results from European Cubicin® Outcomes Registry and Experience (EU-CORE). In: Infectious Diseases and Therapy. 2015 ; Vol. 4, No. 3. pp. 283-296.
@article{205fc76decde49a4982f3a2fae961895,
title = "Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin{\circledR} Outcomes Registry and Experience (EU-CORE)",
abstract = "Introduction: The European Cubicin{\circledR} Outcomes Registry and Experience (EU-CORESM) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE). Methods: Data from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Adverse events (AEs) were recorded during treatment and for up to 30 days post-treatment; follow-up data were collected for 2 years. Results: Of 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4{\%}) right-sided IE (RIE), 414 (67.9{\%}) left-sided IE (LIE), and 47 (7.7{\%}) with both right- and left-sided IE (BRLIE). Overall clinical success was achieved in 80.0{\%} of patients (RIE 88.6{\%}, LIE 76.6{\%} and BRLIE 82.9{\%}). Success rates for methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9{\%}, 71.7{\%} and 66.6{\%} in patients with RIE, LIE and BRLIE, respectively. The overall sustained clinical success rate in patients followed for up to 2 years was 86.7{\%} (RIE 93.5{\%}, LIE 88.3{\%} and BRLIE 77.8{\%}). AEs deemed possibly related to daptomycin in the investigator’s opinion were reported in 2 (1.3{\%}) RIE, 18 (4.3{\%}) LIE and 1 (2.1{\%}) BRLIE patients. There were 11 (1.8{\%}) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly related to daptomycin. Conclusion: Data from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.",
keywords = "Daptomycin, Endocarditis, EU-CORE, Left-sided endocarditis, Right-sided endocarditis",
author = "Achyut Guleri and Riccardo Utili and Pascal Dohmen and Nicola Petrosillo and Cornelia Piper and Rashidkhan Pathan and Kamal Hamed",
year = "2015",
month = "9",
day = "26",
doi = "10.1007/s40121-015-0075-9",
language = "English",
volume = "4",
pages = "283--296",
journal = "Infectious Diseases and Therapy",
issn = "2193-8229",
publisher = "Springer Healthcare",
number = "3",

}

TY - JOUR

T1 - Daptomycin for the Treatment of Infective Endocarditis

T2 - Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

AU - Guleri, Achyut

AU - Utili, Riccardo

AU - Dohmen, Pascal

AU - Petrosillo, Nicola

AU - Piper, Cornelia

AU - Pathan, Rashidkhan

AU - Hamed, Kamal

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Introduction: The European Cubicin® Outcomes Registry and Experience (EU-CORESM) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE). Methods: Data from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Adverse events (AEs) were recorded during treatment and for up to 30 days post-treatment; follow-up data were collected for 2 years. Results: Of 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with both right- and left-sided IE (BRLIE). Overall clinical success was achieved in 80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%). Success rates for methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7% and 66.6% in patients with RIE, LIE and BRLIE, respectively. The overall sustained clinical success rate in patients followed for up to 2 years was 86.7% (RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs deemed possibly related to daptomycin in the investigator’s opinion were reported in 2 (1.3%) RIE, 18 (4.3%) LIE and 1 (2.1%) BRLIE patients. There were 11 (1.8%) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly related to daptomycin. Conclusion: Data from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.

AB - Introduction: The European Cubicin® Outcomes Registry and Experience (EU-CORESM) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE). Methods: Data from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Adverse events (AEs) were recorded during treatment and for up to 30 days post-treatment; follow-up data were collected for 2 years. Results: Of 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with both right- and left-sided IE (BRLIE). Overall clinical success was achieved in 80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%). Success rates for methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7% and 66.6% in patients with RIE, LIE and BRLIE, respectively. The overall sustained clinical success rate in patients followed for up to 2 years was 86.7% (RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs deemed possibly related to daptomycin in the investigator’s opinion were reported in 2 (1.3%) RIE, 18 (4.3%) LIE and 1 (2.1%) BRLIE patients. There were 11 (1.8%) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly related to daptomycin. Conclusion: Data from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.

KW - Daptomycin

KW - Endocarditis

KW - EU-CORE

KW - Left-sided endocarditis

KW - Right-sided endocarditis

UR - http://www.scopus.com/inward/record.url?scp=84977079308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977079308&partnerID=8YFLogxK

U2 - 10.1007/s40121-015-0075-9

DO - 10.1007/s40121-015-0075-9

M3 - Article

AN - SCOPUS:84977079308

VL - 4

SP - 283

EP - 296

JO - Infectious Diseases and Therapy

JF - Infectious Diseases and Therapy

SN - 2193-8229

IS - 3

ER -